Johnson & Johnson banner

Johnson & Johnson
DUS:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
DUS:JNJ
Watchlist
Price: 211.5 EUR 0.98% Market Closed
Market Cap: €509.7B

Relative Value

The Relative Value of one JNJ stock under the Base Case scenario is hidden EUR. Compared to the current market price of 211.5 EUR, Johnson & Johnson is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

JNJ Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

JNJ Competitors Multiples
Johnson & Johnson Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Johnson & Johnson
DUS:JNJ
566.8B EUR 6 21.1 14.7 18.1
US
Eli Lilly and Co
NYSE:LLY
856.7B USD 13.1 41.5 28 29.9
CH
Roche Holding AG
SIX:ROG
243.3B CHF 4 18.9 11.2 12.6
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 4.9 28.3 15.7 22.2
US
Merck & Co Inc
NYSE:MRK
282.6B USD 4.3 15.5 9.6 11.7
CH
Novartis AG
SIX:NOVN
222.2B CHF 5.1 20.5 12.7 16.3
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.7 9
US
Pfizer Inc
NYSE:PFE
153.4B USD 2.5 19.7 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
115.7B USD 2.4 16.4 7 8.6
FR
Sanofi SA
PAR:SAN
93.7B EUR 2 12 10.1 10.1
P/E Multiple
Earnings Growth PEG
US
Johnson & Johnson
DUS:JNJ
Average P/E: 20.4
21.1
7%
3
US
Eli Lilly and Co
NYSE:LLY
41.5
32%
1.3
CH
Roche Holding AG
SIX:ROG
18.9
14%
1.3
UK
AstraZeneca PLC
LSE:AZN
28.3
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
CH
Novartis AG
SIX:NOVN
20.5
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1
FR
Sanofi SA
PAR:SAN
12
16%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Johnson & Johnson
DUS:JNJ
Average EV/EBITDA: 45.4
14.7
2%
7.4
US
Eli Lilly and Co
NYSE:LLY
28
22%
1.3
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
15.7
13%
1.2
US
Merck & Co Inc
NYSE:MRK
9.6
3%
3.2
CH
Novartis AG
SIX:NOVN
12.7
5%
2.5
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.7
1%
7.7
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7
-10%
N/A
FR
Sanofi SA
PAR:SAN
10.1
19%
0.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Johnson & Johnson
DUS:JNJ
Average EV/EBIT: 99.1
18.1
6%
3
US
Eli Lilly and Co
NYSE:LLY
29.9
22%
1.4
CH
Roche Holding AG
SIX:ROG
12.6
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
22.2
21%
1.1
US
Merck & Co Inc
NYSE:MRK
11.7
6%
2
CH
Novartis AG
SIX:NOVN
16.3
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.6
-7%
N/A
FR
Sanofi SA
PAR:SAN
10.1
12%
0.8
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett